Regorafenib

Overview

Regorafenib, also known as BAY 73-4506, is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. Regorafenib is demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the US FDA on September 27, 2012.

Application

Products > Drug Discovery > Impurities > Anti-Neoplastic > Regorafenib and Impurities | Products > Drug Discovery > Inhibitor

Product Information

• Catalog No.: B1813-483713
• CAS No.: 755037-03-7
• Molecular Formula: C21H15ClF4N4O3
• Molecular Weight: 482.83
• Purity: >98%
• Storage: Store at 2-8°C
• Solubility: Soluble in DMSO (Slightly), Methanol (Slightly)

Source

Original product source